Mafalda A Videira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9184693/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Repurposing Natural Dietary Flavonoids in the Modulation of Cancer Tumorigenesis: Decrypting the Molecular Targets of Naringenin, Hesperetin and Myricetin. Nutrition and Cancer, 2022, 74, 1188-1202.	2.0	5
2	Akt/mTOR Activation in Lung Cancer Tumorigenic Regulators and Their Potential Value as Biomarkers. Onco, 2022, 2, 36-55.	0.6	3
3	Picturing Breast Cancer Brain Metastasis Development to Unravel Molecular Players and Cellular Crosstalk. Cancers, 2021, 13, 910.	3.7	14
4	miRNAs in Health and Disease: A Focus on the Breast Cancer Metastatic Cascade towards the Brain. Cells, 2020, 9, 1790.	4.1	14
5	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. Frontiers in Medicine, 2020, 7, 50.	2.6	11
6	AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells. Drug Delivery, 2018, 25, 961-972.	5.7	32
7	Rational Design of a siRNA Delivery System: ALOX5 and Cancer Stem Cells as Therapeutic Targets. Precision Nanomedicine, 2018, 1, 86-105.	0.8	6
8	Brain metastasization of breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 132-147.	7.4	60
9	Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 110, 76-84.	4.3	46
10	Cancer stem cells and personalized cancer nanomedicine. Nanomedicine, 2016, 11, 307-320.	3.3	27
11	Self-assembly PEGylation assists SLN-paclitaxel delivery inducing cancer cell apoptosis upon internalization. International Journal of Pharmaceutics, 2016, 501, 180-189.	5.2	23
12	Targeting AKT2 signalling events: improving therapeutic outcomes through cancer stemness modulation. Annals of Oncology, 2015, 26, ii25.	1.2	0
13	Host-directed strategies using lipid nanoparticles to reduce mycobacteria survival. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	4
14	Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome. Drug Discovery Today, 2015, 20, 1152-1158.	6.4	32
15	Solid state formulations composed by amphiphilic polymers for delivery of proteins: characterization and stability. International Journal of Pharmaceutics, 2015, 486, 195-206.	5.2	25
16	Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1883-1892.	3.3	69
17	In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. Journal of Controlled Release, 2015, 198, 91-103.	9.9	126
18	Looking out for Cancer Stem Cells' Properties: The Value-Driving Role of CD44 for Personalized Medicines. Current Cancer Drug Targets, 2015, 14, 832-849.	1.6	13

MAFALDA A VIDEIRA

#	Article	IF	CITATIONS
19	Regulatory Aspects of Oncologicals: Nanosystems Main Challenges. Advances in Delivery Science and Technology, 2014, , 425-452.	0.4	14
20	Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 689-702.	3.3	48
21	Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy. Procedia in Vaccinology, 2014, 8, 62-67.	0.4	6
22	Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 312-325.	7.4	52
23	Characterisation of DM-β-cyclodextrin:prednisolone complexes and their formulation as eye drops. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2014, 80, 155-164.	1.6	7
24	Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Advanced Drug Delivery Reviews, 2013, 65, 1816-1827.	13.7	187
25	Experimental design towards an optimal lipid nanosystem: A new opportunity for paclitaxel-based therapeutics. European Journal of Pharmaceutical Sciences, 2013, 49, 302-310.	4.0	17
26	Immune system targeting by biodegradable nanoparticles for cancer vaccines. Journal of Controlled Release, 2013, 168, 179-199.	9.9	212
27	Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1208-1215.	3.3	107
28	Biodistribution of Lipid Nanoparticles: A Comparative Study of Pulmonary versus Intravenous Administration in Rats. Current Radiopharmaceuticals, 2012, 5, 158-165.	0.8	5
29	Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine, 2011, 6, 123-141.	3.3	62
30	Micelle-based Systems for Pulmonary Drug Delivery and Targeting. Drug Delivery Letters, 2011, 1, 171-185.	0.5	0
31	Micelle-based Systems for Pulmonary Drug Delivery and Targeting. Drug Delivery Letters, 2011, 1, 171-185.	0.5	15
32	Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres. Biomaterials, 2009, 30, 5161-5169.	11.4	28
33	Lymphatic uptake of lipid nanoparticles following endotracheal administration. Journal of Microencapsulation, 2006, 23, 855-862.	2.8	47
34	Synthesis and biodistribution studies of two novel radioiodinated areno-annelated estra-1,3,5(10),16-tetraene-3-ols as promising estrogen receptor radioligands. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 559-569.	1.0	6
35	Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles. Journal of Drug Targeting, 2002, 10, 607-613.	4.4	213
36	Liquid-liquid extraction of clavulanic acid using an aqueous two-phase system of polyethylene glycol and potassium phosphate. Journal of Chromatography A, 1994, 668, 237-240.	3.7	25

#	Article	IF	CITATIONS
37	Amphiphilic Polymers: Drug Delivery. , 0, , 186-202.		Ο
38	Lipoplexes and Polyplexes: Gene Therapy. , 0, , 4335-4347.		13

Lipoplexes and Polyplexes: Gene Therapy. , 0, , 4335-4347. 38